Do malfunctioning bioprosthetic heart valves represent a potential thrombogenic focus?

Area of Science:

• Cardiology
• Hematology
• Biomaterials Science

Background:

• Bioprosthetic heart valves are common implants, but their long-term function and thrombogenicity remain areas of research.
• Platelet activation plays a crucial role in thrombosis and the function of cardiovascular devices.

Purpose of the Study:

• To investigate in vivo platelet reactivity in patients with well-functioning and malfunctioning bioprosthetic heart valves.
• To determine if bioprosthetic heart valve degeneration correlates with increased platelet activation and potential thrombogenicity.

Main Methods:

• Plasma concentrations of beta-thromboglobulin (beta TG) and platelet factor 4 (PF4) were measured in 57 patients with bioprosthetic heart valves (35 well-functioning, 22 malfunctioning).
• Platelet reactivity markers were compared between malfunctioning bioprostheses (MFBP), well-functioning bioprostheses (WFBP), and control groups.
• Serum lactic dehydrogenase, indirect bilirubin, and reticulocyte counts were assessed to evaluate hemolysis.

Main Results:

• Patients with MFBP exhibited significantly higher plasma beta TG and PF4 concentrations compared to WFBP and control groups.
• No significant difference in beta TG and PF4 was observed between WFBP patients and controls, even with repeated monthly measurements.
• While markers of hemolysis were higher in MFBP patients, no direct correlation was found between platelet reactivity and intravascular hemolysis rate.

Conclusions:

• Increased in vivo release of platelet-specific proteins (beta TG, PF4) occurs in patients with malfunctioning bioprosthetic heart valves.
• Degenerating bioprosthetic heart valves may serve as a thrombogenic focus, independent of mechanical damage or significant hemolysis.